Morgan Stanley Maintains Overweight on IO Biotech, Lowers Price Target to $11
Morgan Stanley analyst Matthew Harrison maintains IO Biotech (NASDAQ:IOBT) with a Overweight and lowers the price target from $15 to $11.
Analyst Says IO Biotech’s Cancer Treatment Approach ‘Differentiated’
HC Wainwright has initiated coverage on Denmark-based cancer firm IO Biotech Inc (NASDAQ:IOBT) with a Buy rating and a price target of $10.…
HC Wainwright & Co. Initiates Coverage On IO Biotech with Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Emily Bodnar initiates coverage on IO Biotech (NASDAQ:IOBT) with a Buy rating and announces Price Target of $10.
IO Biotech Q3 EPS $(0.56)
IO Biotech (NASDAQ:IOBT) reported quarterly losses of $(0.56) per share.
Why Is Infrastructure and Energy Alternatives Higher By Around 29%? 37 Stocks Moving In Monday’s Mid-Day Session
Gainers
Revelation Biosciences, Inc. (NASDAQ: REVB) jumped 104% to $1.3263 after the company announced that primary endpoint was met in study for its treatment of allergic rhinitis.
Tesla, Coinbase Global And 41 Stocks Moving In Monday’s Mid-Day Session
Gainers
Intelligent Living Application Group Inc. (NASDAQ: ILAG) shares jumped 90.2% to $4.2792 after declining 11% on Friday. The company reported closing of $20.24 million initial public offering.
IO Biotech Starts Dosing In Late-Stage IO102-IO103/Keytruda Combo Trial In Melanoma Patients
IO Biotech (NASDAQ: IOBT) dosed first patient in its phase 3 clinical trial of lead drug candidate, IO102-IO103, in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with previously untreated, unresectable or metastatic (advanced) melanoma.